首页> 外国专利> METHOD FOR MORPHOMETRIC EVALUATION OF IMMUNE THROMBOCYTOPENIA COURSE PREDICTION AFTER SPLENECTOMY BASED ON SPLEEN CD4+/CD8+ T-LYMPHOCYTES WEIGHTS RATIO

METHOD FOR MORPHOMETRIC EVALUATION OF IMMUNE THROMBOCYTOPENIA COURSE PREDICTION AFTER SPLENECTOMY BASED ON SPLEEN CD4+/CD8+ T-LYMPHOCYTES WEIGHTS RATIO

机译:基于脾脏CD4 + / CD8 + T淋巴细胞权重比的脾脏切除术后免疫性血小板减少症病程预测的方法

摘要

FIELD: medicine.;SUBSTANCE: to implement the invention, the weight of the removed spleen is determined, histologic diagnosis of the postoperative material samples is performed in a conventional manner with preparation of paraffin blocks. To identify and count CD4+ and CD8+ lymphocytes, immunohistochemical staining is performed in histological sections of the spleen. In the spleen histological sections, the number of CD4+ and CD8+ cells is counted, their weight is calculated and the mass index ratio (MIR) of CD4+/CD8+ T-lymphocytes is calculated. At CD4+/CD8+ T-lymphocyts MIR values 2.3, a refractory form of immune thrombocytopenia is predicted, and at ≥2.4, the favorable course of the disease is concluded.;EFFECT: use of the invention provides effective morphometric assessment of immune thrombocytopenia course after splenectomy.;2 ex
机译:技术领域:药物:物质:为了实施本发明,确定去除的脾脏的重量,以常规方式通过制备石蜡块来进行术后材料样品的组织学诊断。为了鉴定和计数CD4 +和CD8 +淋巴细胞,在脾的组织学切片中进行免疫组织化学染色。在脾组织学切片中,计数CD4 +和CD8 +细胞的数量,计算其重量,并计算CD4 + / CD8 + T淋巴细胞的质量指数比(MIR)。在CD4 + / CD8 + T淋巴细胞的MIR值<2.3时,可以预测难治性免疫性血小板减少症,而在≥2.4时,可以得出该病的有利病程。脾切除后;; 2前

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号